However, several previous clinical studies, including ours, have shown that high levels of selenium are associated with the risk of developing MAFLD, positively correlated with hepatic steatosis (8, 9, 31–33) and positively correlated with changes in liver function, with Se being most significantly associated with changes in ALT (7). This evidence concerns the gene GPT and fatty liver disease.